IntelliCell BioSciences, Inc. Announces it Has Opened an Adipose Tissue Processing Center in New Orleans
News Aug 26, 2011
IntelliCell BioSciences, Inc., has announced it has opened an Adipose Stem Cell Processing Center in New Orleans, Louisiana. This center will make adipose derived stem cells available for doctors in the metro New Orleans area.
The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia.
Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly.
Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.
"We believe IntelliCell is setting the gold standard for adipose stem cell processing. Our technology provides stem cell counts and viability checks for each specimen processed, as well as documents the quality and quantity of the stem cells produced. The Company's entry into the New Orleans market will grant us the opportunity to offer this community of physicians, researchers, and healthcare centers access to, what we believe to be, the highest number and quality stromal vascular fraction (SVF) cells which contain adult stem cells through our proprietary, FDA compliant, process. We are very pleased to see New Orleans receive this promising service," stated IntelliCell Chairman and CEO, Dr. Steven Victor.
IntelliCell's adipose stem cell processing technique takes approximately 30 minutes and the stem cells can be returned to the doctor in the same day. Autologous Adipose stem cells are on the cutting edge of medicine and IntelliCell is excited to be one of the companies to participate in this field.
IntelliCell has developed an in-house technology where it can easily process stromal vascular cells containing a high concentration of adipose stem cells with excellent viability.
At present, management believes it is the only company that does not use enzymes in processing adipose tissue and actually counts and checks the adipose stem cells they manufacture.